just bought 12000 shares @.19 -- great spec buy here!! hoping to add more! spread the word..
Advanced Medical Isotope Corp. (ADMD.OB), also referred to as AMIC, is a budding development-phase company that has witnessed its common shares advance by more than 180% YTD. The company has been developing its capabilities to produce radioisotopes to be used for diagnostic imaging and radiotherapy for the last couple of years, but now appears to be advancing a bit more rapidly. On April 12th of this year, AMIC announced its first contract in which it would supply medical isotopes for Kennewick General Hospital of Kennewick, Washington. Although not mentioned in the press release, the utilized isotope is fluorine-18 (F-18), the isotope most widely used for PET (positron emission tomography), a commonly used diagnostic tool used to produce high-quality, 3D images in evaluating cancers, cardiac disease, and brain function. Although details of the contract were not revealed, the company's recent Q3 filing indicated revenue for the period, most likely the result of this contract. For the three months ending September 30th, the company reported revenue of $62K, with $181K for the nine month period. This is still construed as a development-phase company, as its $13 million market capitalization reflects. However, real revenue for a small company like this with a real product is significant and could lead to bigger contracts in the coming days and months as it continues to grow its network of contacts.
AMIC's potential is two-fold. Its initial business model and only source of revenue is medical isotope production. Early in the development of its business, the company already has a network of universities (SUNY Buffalo, Idaho State University, and University of Missouri) and three U.S. national laboratories (Pacific Northwest National Laboratory, Los Alamos National Laboratory, and Lawrence Berkeley National Laboratory) enlisted in its early work in isotope production and pertinent application research. The company's growth strategies as noted on its website, give investors food for thought in the terms of many possible upcoming press releases. For example, consider the following statements:
AMIC began formal negotiations for the creation of strategic relationships to produce and sell medical isotopes in Taiwan and China.
Initiated discussions for the construction of regional PET isotope production centers in Los Angeles, California and Oahu, Hawaii.
AMIC commenced three international advanced technology collaborative development projects for production and isotopic separation capability, offering high-value products not available from other sources.
Completed a strategic acquisition of a competitive firm, thereby establishing AMIC's position as a marketplace supplier through international sales of the O-18 isotope.
Updates on any of these with possibilities of contracts or revenue coming could provide for significant share price movement. In the company's Q2 financials was another obscure statement providing for evidence of possible news in future. In the filing, the company noted "We currently offer regional distribution of F-18 from our Kennewick, WA production facility. Other regional production facilities are being considered throughout the U.S. and abroad."
Possible catalysts loom large for this microcap company due to potential contracts and news of developments pertaining to its increasing capacity to produce medical isotopes through its linear accelerator technologies rather than the industry's normal source of nuclear reactors. However, an announcement from April 12th of this year dramatically increased shareholder interest in the company and diversified its business model by adding a clinical-stage therapy candidate to its product line. The company announced that it had obtained an exclusive license to eight patents for injectable radiogel technology for use in high-dose radiation therapy from Battelle, the world's largest nonprofit research and development company. Radiogel is comprised of a water-based biodegradable polymer that contains the medical isotope, yttrium-90 (Y-90). The product is injected into targeted cancer tumors where it then polymerizes into a lattice (cage-like structure) that is immobile and traps the Y-90 microspheres. The Y-90 emits high-energy beta radiation which is therapeutic by killing local cancer cells that are more susceptible to the cytotoxic effects of radiation than normal, healthy cells. This offers the same therapeutic effects as externally-administered radiation treatments with a focus on only cancer tumors while having minimal systemic exposure to the harmful side effects. Y-90 has a short life as indicated by its 64.2 hour half life. In 64.2 hours after administration, half of the material has decayed to the stable zirconium-90. In another 64.2 hours later, half of the remaining has decayed and so forth. By the 11th day after administration, over 94% of the radiation has been emitted, leaving little to negatively affect the safety profile of the treatment regimen. The remaining polymer lattice degrades and is absorbed by and excreted by the body.
Although the company hasn't recently released an update on the radiogel product, an April 2012 company presentation by the company CEO, James Katzaroff, gives investors an idea of what could be coming. On slide number eight, the company noted "Animal studies and testing for FDA 510(K) approval about to begin. Approval is projected in 2013." Not a company given to excessive press releases or updates, an update on the initiation (or completion) of these trials or a 510(K) (medical device application for marketing approval) application could be a huge share price mover for this company's common shares.
Advanced Medical Isotope Corp. is not an investment for every investor type. The company should be considered as a development-phase company with minimal revenue currently. It is traded on the OTCBB exchange which is more subject to share price manipulation and illiquidity at times. Interested investors are advised to perform considerable research into the company, its medical isotopes product and research work, its radiogel technology now being developed and then any SEC filings from the last couple of years before opening a position in the company's common shares. There is risk here, but the $13 million market capitalization appears to take that into consideration. The upside here could be significant depending on how the company's business model unfolds. Shareholders could witness an exciting 2013 ahead for this promising and increasingly-diverse company.
This is a wise investment boys. The reason I invest is because I see how unique this corporation is and I think that RADIOGEL is ingenius and clever. The corporation is tackling various aspects of business and making some smart moves.
Best advice I could give is to put Stupid in Seattle on ignore. Hard to find another idiot who knows less about ADMD and investing in bio tech then Stupid in Seattle. My black lab is smarter then this A- wipe.